Shares of Bausch Health Companies Inc (NYSE: BHC) surged over 5% in pre-market trading on Thursday, driven by the company's strong fourth quarter 2024 earnings report and positive outlook for 2025. The healthcare company, which specializes in eye care products, saw its stock price climb following its Q4 earnings call, where it highlighted its robust innovation pipeline and successful execution across its vision care, surgical, and pharmaceuticals businesses.

Bausch Health reported double-digit constant currency revenue growth for the full year 2024, led by standout performances from its key franchises. The company's Miebo dry eye drug continued its impressive launch trajectory, with Bausch expressing confidence in its path to profitability starting in 2026. The company's premium intraocular lens (IOL) offerings, including the recently launched Envy and LuxLife lenses, saw strong growth, contributing to an 11% revenue increase in the surgical segment for the year.

Looking ahead, Bausch Health's CEO Brent Saunders highlighted the company's robust pipeline of innovative products across its businesses, including a first-of-its-kind biomimetic contact lens, a myopia control solution, and novel treatments for glaucoma and chronic ocular surface pain. The company's focus on leveraging cutting-edge technologies, such as AI and machine learning, in its manufacturing and sales processes, was also emphasized as a key driver of future growth and efficiency.

While the company's strong performance and positive outlook fueled investor optimism, analysts at Truist Financial maintained a Hold rating on the stock, suggesting some caution or uncertainty around Bausch Health's prospects.